US FDA provides insight into communication commitments with device makers
This article was originally published in SRA
The US Food and Drug Administration has issued updated guidance that describes the types of communications the agency is using to engage with medical device companies when reviewing marketing applications1,2.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.